Centre for Systems Chemistry, Stratingh Institute for Chemistry, University of Groningen , Nijenborgh 4, 9747 AG Groningen, The Netherlands.
Molecular Microbiology, Groningen Biomolecular Sciences and Biotechnology Institute , Nijenborgh 7 9747 AG Groningen, The Netherlands.
J Am Chem Soc. 2017 Dec 13;139(49):17979-17986. doi: 10.1021/jacs.7b09281. Epub 2017 Nov 28.
The field of photopharmacology aims to introduce smart drugs that, through the incorporation of molecular photoswitches, allow for the remote spatial and temporal control of bioactivity by light. This concept could be particularly beneficial in the treatment of bacterial infections, by reducing the systemic and environmental side effects of antibiotics. A major concern in the realization of such light-responsive drugs is the wavelength of the light that is applied. Studies on the photocontrol of biologically active agents mostly rely on UV light, which is cytotoxic and poorly suited for tissue penetration. In our efforts to develop photoswitchable antibiotics, we introduce here antibacterial agents whose activity can be controlled by visible light, while getting into the therapeutic window. For that purpose, a UV-light-responsive core structure based on diaminopyrimidines with suitable antibacterial properties was identified. Subsequent modification of an azobenzene photoswitch moiety led to structures that allowed us to control their activity against Escherichia coli in both directions with light in the visible region. For the first time, full in situ photocontrol of antibacterial activity in the presence of bacteria was attained with green and violet light. Most remarkably, one of the diaminopyrimidines revealed an at least 8-fold difference in activity before and after irradiation with red light at 652 nm, showcasing the effective "activation" of a biological agent otherwise inactive within the investigated concentration range, and doing so with red light in the therapeutic window.
光药理学领域旨在引入智能药物,通过分子光开关的引入,可以通过光实现生物活性的远程时空控制。这一概念在治疗细菌感染方面特别有益,因为可以减少抗生素的全身和环境副作用。实现这种光响应药物的一个主要问题是所应用光的波长。关于生物活性物质光控制的研究大多依赖于紫外线,而紫外线具有细胞毒性,并且不适合组织穿透。在我们开发光致动抗生素的努力中,我们在这里引入了其活性可以通过可见光控制的抗菌剂,同时进入治疗窗口。为此,我们确定了一种基于二氨基嘧啶的具有合适抗菌性能的 UV 光响应核心结构。随后对偶氮苯光开关部分进行修饰,得到了结构,使我们能够用光在可见光区域的两个方向控制它们对大肠杆菌的活性。首次在存在细菌的情况下,通过绿光和紫光实现了对抗菌活性的完全原位光控。最值得注意的是,其中一种二氨基嘧啶在红光(652nm)照射前后的活性差异至少为 8 倍,展示了一种原本在研究浓度范围内无活性的生物制剂的有效“激活”,并且使用的是治疗窗口中的红光。